Number Needed to Treat and Cost Per Responder Analysis of Anti-CGRP Monoclonal Antibodies for Migraine Prevention in Adults for Whom Prior Preventive Treatments have Failed.
Number Needed to Treat and Cost Per Responder Analysis of Anti-CGRP Monoclonal Antibodies for Migraine Prevention in Adults for Whom Prior Preventive Treatments have Failed.
D. Mitsikostas,Susanne F Awad,4 Authors,Simona Sacco
2025 · DOI: 10.1007/s12325-025-03348-8
Advances in Therapy · 0 Citations
TLDR
These results show that, for most anti-CGRP mAbs, a low number of participants with migraine need to be treated to achieve one person with a ≥ 50% or ≥ 75% reduction in MMDs over Weeks 1-12.